

Brazilian Journal of Medical and Biological Research (2009) 42: 21-28  
ISSN 0100-879X Review

# The inhibitory role of sympathetic nervous system in the $\text{Ca}^{2+}$ -dependent proteolysis of skeletal muscle

L.C.C. Navegantes<sup>1</sup>, A.M. Baviera<sup>2</sup> and I.C. Kettelhut<sup>3</sup>

<sup>1</sup>Departamento de Fisiologia, <sup>3</sup>Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil

<sup>2</sup>Departamento de Química, Universidade Federal do Mato Grosso, Cuiabá, MT, Brasil

Correspondence to: L.C.C. Navegantes, Departamento de Fisiologia, FMRP, USP, Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brasil

Fax: +55-16-3633-0017. E-mail: navegantes@fmrp.usp.br

Mammalian cells contain several proteolytic systems to carry out the degradative processes and complex regulatory mechanisms to prevent excessive protein breakdown. Among these systems, the  $\text{Ca}^{2+}$ -activated proteolytic system involves the cysteine proteases denoted calpains, and their inhibitor, calpastatin. Despite the rapid progress in molecular research on calpains and calpastatin, the physiological role and regulatory mechanisms of these proteins remain obscure. Interest in the adrenergic effect on  $\text{Ca}^{2+}$ -dependent proteolysis has been stimulated by the finding that the administration of  $\beta_2$ -agonists induces muscle hypertrophy and prevents the loss of muscle mass in a variety of pathologic conditions in which calpains are activated. This review summarizes evidence indicating that the sympathetic nervous system produces anabolic, protein-sparing effects on skeletal muscle protein metabolism. Studies are reviewed, which indicate that epinephrine secreted by the adrenal medulla and norepinephrine released from adrenergic terminals have inhibitory effects on  $\text{Ca}^{2+}$ -dependent protein degradation, mainly in oxidative muscles, by increasing calpastatin levels. Evidence is also presented that this antiproteolytic effect, which occurs under both basal conditions and in stress situations, seems to be mediated by  $\beta_2$ - and  $\beta_3$ -adrenoceptors and cAMP-dependent pathways. The understanding of the precise mechanisms by which catecholamines promote muscle anabolic effects may have therapeutic value for the treatment of muscle-wasting conditions and may enhance muscle growth in farm species for economic and nutritional purposes.

Key words: Epinephrine; Norepinephrine; Calpastatin; Calpain; Skeletal muscle

Presented at the IV Miguel R. Covian Symposium, Ribeirão Preto, SP, Brazil, May 23-25, 2008.

Research supported by FAPESP (#04/02674-0 and #06/0697-3) and CNPq (#305847/06-6 and #300440/05-7).

Received August 1, 2008. Accepted December 4, 2008

## Introduction

The sympathetic nervous system (SNS) utilizes two major chemical signaling molecules: epinephrine (adrenaline) that is secreted directly into the blood from the adrenal medulla, and norepinephrine (noradrenaline) that is the major neurotransmitter produced and released from peripheral sympathetic neurons, which are distributed widely to different tissues and are associated with blood vessels.

Although it is well known that skeletal muscles receive a cholinergic innervation from the motoneuron, evidence indicates that adrenergic nerve terminals make close contact with striated muscle fibers in mammals (1). However, the physiological role of this innervation is far from being well established.

It is well known that most of the metabolic actions of the SNS in several tissues are exerted through a  $\beta$ -adrenoceptor-mediated increase in intracellular cyclic adenosine

monophosphate (cAMP) and subsequent activation of cAMP-dependent protein kinase (PKA). The intracellular concentration of cAMP in cells is determined via the balance between cAMP production by adenylyl cyclase, and cAMP degradation by phosphodiesterases (PDEs). Skeletal muscle contains numerous isoforms of PDE, including PDE4, PDE7 and PDE8 (2). However, PDE4 appears to contribute to the majority of cAMP degradation in this tissue (3).

Historically, the physiological role of SNS is related to a "fight or flight" response that prepares an organism to cope with an emergency. Catecholamines decrease the uptake of glucose in peripheral tissues, partly through an inhibition of insulin secretion, stimulate glycogenolysis (4), increase the diet-induced thermogenesis in brown adipose tissue (5), stimulate the substrate oxidation in skeletal muscle (4), and have a well-known stimulatory effect on white adipose tissue lipolysis (6). They also have a marked effect on protein metabolism in skeletal muscle. Numerous studies have shown that  $\beta_2$ -adrenergic agonists, such as clenbuterol and cimaterol, induce hypertrophy of skeletal muscle in livestock and humans (7).  $\beta$ -agonist-induced hypertrophy seems to be specific for striated muscle, since the smooth muscle of the gut, liver, and kidney (8) do not increase in size in response to these agents. It has also been reported that treatment with  $\beta_2$ -adrenergic agonists reduces muscle wasting in different catabolic situations including tumors, atrophy denervation, sepsis, muscular dystrophy, hindlimb suspension, hyperthyroidism, burning, and diabetes (7,9,10). However, the biochemical mechanisms of these effects of  $\beta_2$ -adrenergic agonists are not completely understood.

Skeletal muscle protein mass depends on the balance between synthesis and degradation. Even a small decrease in synthesis or a small acceleration of degradation, if sustained, can result in a marked loss of mass in the organism (11,12). The main intracellular proteolytic systems in the skeletal muscles are the lysosomal, the  $\text{Ca}^{2+}$ -dependent, and the ubiquitin-proteasome system. During the last decade, we have been studying the mechanisms through which the rates of these different proteolytic components are regulated by hormonal, nutritional and neural factors. This review will focus on recent studies of the influence of the SNS on  $\text{Ca}^{2+}$ -dependent proteolysis, as well as on the mechanisms involved.

### **The role of the sympathetic nervous system on muscle protein breakdown**

Knowledge of the regulatory factors involved in the control of the rates of protein degradation is important for

understanding the mechanisms by which hormones, neurotransmitters, nutrition, growth promoting agents, and environmental and genetic factors influence growth. In order to investigate the physiological role of catecholamines in the control of protein breakdown in skeletal muscles, we have been using the chemical sympathectomy experimental model in which rats are treated with guanethidine for a few days (13). Guanethidine was chosen because it has been shown to produce a selective blockade of norepinephrine release from peripheral nerves without affecting central adrenergic neurons (14). Guanethidine treatment induces a drastic 90% reduction in norepinephrine content of soleus muscles and a 40-80% reduction in plasma levels of norepinephrine and epinephrine (13). After 1 and 2 days of guanethidine treatment, there was a significant 20% increase in the rate of proteolysis in incubated soleus muscles. Because this early rise in the proteolytic rate occurred without a concomitant change in the plasma levels of other hormones, it was interpreted to be a direct consequence of the depletion of muscle norepinephrine and/or of the reduction in plasma catecholamine concentration induced by guanethidine treatment. Also, the acute increase in proteolysis after adrenergic blockade suggested the existence of an inhibitory adrenergic tonus in oxidative skeletal muscles, which restrains proteolysis (13). In agreement with this suggestion, we have found that both epinephrine and norepinephrine, added *in vitro*, reduce the rate of protein degradation in normal rat soleus and extensor digitorum longus (EDL) by approximately 15-20% (15). This view is consistent with the finding that infusion of epinephrine in muscle microdialysis experiments (16), in perfused rat hindquarters (17) and in humans (18) induces a rapid and similar 20% decrease in protein degradation.

Recently, we have investigated the role of the SNS in the control of protein degradation in skeletal muscles from rats with streptozotocin (STZ)-induced diabetes (19). It has been shown that chemical sympathectomy by guanethidine further increased the high rate of protein degradation in soleus and EDL muscles during the early stages of diabetes in rats (1 and 3 days after STZ). Although guanethidine treatment induced a decrease in both plasma epinephrine and muscle norepinephrine, the additional increase in the proteolysis observed in muscles from sympathectomized diabetic rats was probably a consequence of the reduction in plasma epinephrine concentration (19). It has been found that the acute reduction in rat plasma catecholamines produced by surgical removal of the adrenal medulla, with no change in muscle norepinephrine content, is accompanied by a transient increase in the rate of skeletal muscle proteolysis (20). It has also been shown

that the infusion of epinephrine in humans and animals induces a rapid decrease in the activity (21) and gene expression (22) of enzymes involved in muscle protein breakdown. The fact that the effects of sympathectomy were obtained in a condition of an acute catabolic state, like diabetes, supports our previous hypothesis based on experiments with chemical sympathectomy of normal rats, that the SNS exerts an acute effect on skeletal muscle protein metabolism, reducing proteolysis. This anabolic effect of the SNS can be interpreted as a mechanism to spare muscle protein in a situation of catabolism. In fact, the drastic reduction of the catecholamine levels in diabetic-sympathectomized rats promoted an additional fall in the body weight of these animals compared to the diabetic group (19).

The finding that soleus was more sensitive than EDL to the catabolic effect of sympathectomy in diabetic rats (19) is consistent with our previous demonstration (15) that soleus is more sensitive than EDL to the antiproteolytic effect of epinephrine *in vitro*. This differential sensitivity may be explained by differences in the density of  $\beta$ -adrenoceptors and levels of PKA, which have been shown to be higher in rat skeletal muscles rich in type I fibers (e.g., soleus) than in muscles containing mainly type II fibers (e.g., EDL) (23,24). That the adrenergic inhibitory effects on skeletal muscle proteolysis are mediated by  $\beta_2$ -adrenoceptors had already been suggested by the *in vivo* hypertrophic effect of the  $\beta_2$ -adrenergic agonists on skeletal muscle of different species and by the suppression of the clenbuterol-induced hypertrophy of rat gastrocnemius muscles by oral administration of ICI 118,551, a selective  $\beta_2$ -adrenoceptor antagonist (25). Recent experiments from our laboratory strongly support this hypothesis by demonstrating directly in isolated skeletal muscle the mediation by  $\beta_2$ -adrenoceptors. Thus, the antiproteolytic effect of epinephrine in soleus and EDL was completely suppressed by propranolol and by ICI 118,551 (13). Clenbuterol *in vitro* induced a dose-dependent inhibition of proteolysis that was also prevented by ICI 118,551 in both muscles (20). Numerous studies have shown that  $\beta_3$ -adrenergic receptors are also present in skeletal muscle (26,27). The presence in skeletal muscle of other types of  $\beta$ -receptors, different from  $\beta_1$ - and  $\beta_2$ -adrenoceptors, was initially surmised from the observation by Reeds et al. (28) that propranolol blocked the clenbuterol-induced decrease in body fat, but was not capable of reverting the increase in rat skeletal muscle growth promoted by the  $\beta_2$ -agonist. This finding suggested the existence of  $\beta$ -adrenoceptor-mediated responses clearly distinct from those mediated by  $\beta_1$ - and  $\beta_2$ -adrenoceptors in muscle. The presence of functional  $\beta_3$ -adrenergic receptors in muscle has been

suggested by the metabolic effects of specific agonists *in vitro* (29) and by the detection of the  $\beta_3$ -adrenoceptor protein and its mRNA in human (26) and rat (27) skeletal muscle. The physiological role of muscle  $\beta_3$ -adrenoceptor, however, remains poorly understood. We have previously shown that CL-316,243, a selective  $\beta_3$ -adrenoceptor agonist, exerts an inhibitory action on proteolysis in rat-isolated soleus muscle. The inhibition of proteolysis induced by the addition of CL-316,243 to the incubation medium of soleus muscles from fed and fasted rats was completely prevented by SR-59230A, a selective  $\beta_3$ -antagonist, but was not affected by selective  $\beta_1$ - or  $\beta_2$ -antagonists (30). Furthermore, we have demonstrated that the inhibitory effect of epinephrine on muscle protein degradation can also be prevented by SR-59230A, suggesting that this adrenergic effect may be mediated by  $\beta_3$ -adrenoceptors (30). It was interesting to note that, unlike soleus, the overall rates of proteolysis observed in fast-twitch muscles, such as EDL, from fed and fasted rats was not affected by CL-316,243. Taken together, these results suggest that epinephrine inhibits proteolysis by activating  $\beta_2$ - and/or  $\beta_3$ -adrenoceptors in oxidative muscles such as soleus (20,30). Further experiments are needed to determine the relative sensitivity of the different muscle fiber types to the  $\beta_3$ -adrenergic agonist-mediated effects on proteolysis.

### Mechanism of adrenergic inhibition of the $\text{Ca}^{2+}$ -dependent proteolysis

The intracellular  $\text{Ca}^{2+}$ -dependent proteolytic system contains at least two ubiquitous enzymes:  $\mu$ - (low  $\text{Ca}^{2+}$ -requiring form) and m-calpain (high  $\text{Ca}^{2+}$ -requiring form). Calpains do not degrade proteins to amino acids or even to small peptides (31,32). In fact, calpains initiate myofibrillar protein degradation by disassembling the outer layer of proteins from the myofibril and releasing them as myofilaments. Although the proteasome, the proteolytic enzymatic complex of the ubiquitin-proteasome system, can degrade the majority of intracellular proteins, it cannot degrade myofibrillar proteins until they have been removed from the myofibril by calpains. Therefore, it appears that both calpains and the proteasome are responsible for myofibrillar protein turnover. Calpains tend to be concentrated in the Z band of the sarcomere (33), the site where disassembly begins (34). Since skeletal muscle cells contain sufficient calpain to destroy all Z bands in these cells in 5-10 min, it is likely that in physiological conditions calpain activity must be inactive most of the time (32). Calpain activity is regulated by a variety of factors, including  $\text{Ca}^{2+}$ , phospholipids, a 30-kDa small calpain subunit, and calpastatin, a widely distributed calpain-specific endoge-

nous inhibitor (35). It is generally thought that the calpain-calpastatin system plays a major role in muscle protein degradation only when cytosolic  $\text{Ca}^{2+}$  homeostasis is altered. Recent findings showing that calpastatin overexpression results in skeletal muscle hypertrophy (36) and protects mice against atrophy (37) provide evidence that calpastatin is also involved in the control of normal skeletal muscle protein turnover. However, the physiological role of neural and peripheral signals implicated in the control of calpain and calpastatin activity in *in vivo* conditions is still unknown.

In previous studies, we have demonstrated that the increase in overall proteolysis observed after 2 days of chemical (13) and surgical sympathectomy (20) is accompanied by a parallel increase in the activity of the  $\text{Ca}^{2+}$ -dependent system, suggesting that the restraining effect of the adrenergic tonus on skeletal muscle proteolysis is exerted, at least in part, by keeping the  $\text{Ca}^{2+}$ -dependent pathway inhibited. In agreement with these results, the inhibitory *in vitro* effect of clenbuterol and CL-316,243 on the rate of overall proteolysis in isolated skeletal muscle from normal rats was shown to be associated with a reduction in the activity of the  $\text{Ca}^{2+}$ -dependent proteolysis, an effect that was prevented by selective  $\beta_2$ - and  $\beta_3$ -antagonists (20,30).

In view of the antiproteolytic effect of the SNS in skeletal muscles from normal rats, recent studies were undertaken in our laboratory to examine the changes in the rate of protein synthesis and activity of the different proteolytic systems, which occur in oxidative muscles from rats submitted to 9 days of chronic intermittent hypoxia (CIH; 6%  $\text{O}_2$  for 40 s at 9-min intervals; 8 h/day). Studies have shown that rats submitted to CIH exhibited a higher level of basal sympathetic activity, which, in turn, increased arterial pressure (38,39). In addition to the lower rates of protein synthesis observed in soleus muscles from rats exposed to CIH, we also found a reduction in the rates of proteolysis (Fabio TL, Gonçalves DA, Lira EC, Zanon NM, Bonagamba LG, Zoccal DB, Kettelhut IC, Machado BH, Navegantes LCC, unpublished data). The CIH-induced inhibition of muscle proteolysis in rats was probably a direct consequence of the muscle sympathoexcitation and can be interpreted as an adaptive response of protein metabolism that helps to prevent excessive loss of skeletal muscle mass during prolonged hypoxic stress. Maintenance of protein content is especially essential for red, oxidative muscles, such as soleus, which serve the important function of sustaining most of the postural work of the animal. The decrease in the overall proteolysis in soleus muscles from rats exposed to CIH was accompanied by ~50% decrease in the activity of muscle  $\text{Ca}^{2+}$ -dependent pro-


teolytic pathway, with no changes in the activities of the lysosomal and ubiquitin-proteasome systems. There is a growing body of evidence that the activity and gene expression of calpastatin are increased after  $\beta_2$ -adrenergic agonists treatment (40-42), leading to the suggestion that this is the mechanism of the inhibitory effect of catecholamines on the  $\text{Ca}^{2+}$ -dependent proteolysis. This hypothesis has been reinforced by the findings that CIH induces an increase in calpastatin levels in soleus muscles from rats. Similar results have been observed in soleus from rats treated with clenbuterol for 3 days (Gonçalves DA, Baviera AM, Lira EC, Zanon NM, Kettelhut IC, Navegantes LC, unpublished data) and in muscles from humans after acute exercise (43). Because catecholamines and  $\beta$ -agonists activate PKA and may act via cAMP responsive elements (CRE) in calpastatin promoter regions (44), it has been proposed that calpastatin is a target for this kinase. In agreement with this hypothesis, it has been shown that calpastatin is phosphorylated by PKA (45) and its maximal inhibitory activity against m-calpain is enhanced by phosphorylation in rat skeletal muscle *in vitro* (46). Moreover, recent evidence indicates that the calpastatin gene promoter is activated in rat muscle L6G8 cells transfected with dibutyryl-cAMP or forskolin (47), suggesting that both the calpastatin gene promoter and protein are targets for PKA activity. The inhibition of  $\text{Ca}^{2+}$ -dependent proteolysis by nonhydrolyzable cAMP analogs and the activation of  $\beta_2$ -adrenergic receptor *in vitro* inhibit proteolysis in skeletal muscle from normal rats (20) and chicks (48) are also consistent with the results of the studies cited above.

These findings indicate that cAMP signaling may play an important role in preventing proteolysis in physiological conditions and raise the possibility of using drugs that induce an increase in the intracellular concentrations of cAMP, as the cAMP-PDE inhibitors, to prevent muscular atrophy in several pathological situations. A nonselective PDE inhibitor (pentoxifylline; PTX) or two different selective PDE4 inhibitors (cilomilast and rolipram) have been administered to mice undergoing muscle atrophy, in order to reduce skeletal muscle cAMP degradation, and thus increase cAMP-mediated muscle hypertrophy (49,50). The selective PDE4 inhibitor rolipram was shown to inhibit protein degradation in muscles from normal rats (Lira EC, Gonçalves DA, Baviera AM, Zanon NM, Kettelhut IC, Navegantes LC, unpublished data) and to prevent the muscle wasting and weakness associated with sciatic nerve resection and limb casting (49). Treatment with PTX induced a clear reduction in the high rates of muscle protein degradation in tumor-bearing rats (51) and during sepsis (52). In another study from our laboratory, Lira et al. (53) perfused skeletal muscles from normal and septic rats

with isobutylmethylxanthine, a nonselective PDE inhibitor, and demonstrated that this compound increased muscle cAMP levels and reduced muscle protein catabolism by inhibiting proteolysis. More recently, Baviera et al. (54) also demonstrated that the *in vivo* and *in vitro* treatment with PTX increased muscle cAMP levels and induced a decrease in the increased rate of total protein degradation in EDL muscles from diabetic animals through a clear reduction in the activity of the  $\text{Ca}^{2+}$ -dependent and ubiquitin-proteasome-dependent proteolytic systems, two degradative processes well known to be activated in the acute phase of experimental diabetes (55). The antiproteolytic effect of PTX *in vitro* was inhibited by H89, a PKA inhibitor, further supporting the idea that activation of the cAMP cascade via a PKA-dependent pathway is one of the regulatory mechanism(s) to prevent excessive skeletal

muscle protein breakdown. Although the PKA signaling pathway is the most commonly studied  $\beta$ -adrenoceptor effector in skeletal muscle (7), other studies have shown that the production of cAMP by epinephrine in skeletal muscle (56) may activate a novel protein termed EPAC (exchange protein directly activated by cAMP). Therefore, the possibility of PKA-independent signaling pathways in regulating proteolysis cannot be ruled out.

Figure 1 illustrates the possible mechanisms by which  $\text{Ca}^{2+}$ -dependent proteolysis could be regulated by the SNS *in vivo*. Catecholamines bind directly to  $\beta_2$ - and  $\beta_3$ -adrenoceptors located in the sarcolemma, stimulate adenylate cyclase activity, and consequently increase cAMP, which stimulates PKA in skeletal muscles. This kinase could increase calpastatin activity by direct phosphorylation and/or by increasing the levels of calpastatin mRNA by



**Figure 1.** Mechanisms in the inhibition of the  $\text{Ca}^{2+}$ -dependent proteolysis in skeletal muscle by catecholamines and  $\beta$ -agonists.  $\text{Gs}\alpha$  = stimulatory alpha subunit of guanine nucleotide-binding regulatory protein;  $\beta\gamma$  = beta-gamma subunit of guanine nucleotide-binding regulatory protein; ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; 5'AMP = 5'adenosine monophosphate; PTX = pentoxifylline; IBMX = isobutylmethylxanthine; PDEs = phosphodiesterases; PKA = cAMP-dependent protein kinase; CREB = cAMP responsive element binding protein.



enhanced gene transcription through phosphorylation of the cAMP responsive element binding protein (CREB) and activation of CRE, which could keep the calpain activity inhibited. Alternatively, calpain itself might be inhibited by catecholamines through PKA-induced phosphorylation. In fact, evidence in fibroblasts indicates that m-calpain can be directly phosphorylated and inhibited by PKA (57). More recently, it has been demonstrated that  $\beta_2$ -adrenergic agonist treatment attenuates muscle atrophy induced by hindlimb unweighting or atrophy denervation through inhibitory effects on ubiquitin-proteasome system (58,59). Thus, it could be speculated that proteasome and/or the process of protein ubiquitination is also regulated by PKA and/or EPAC.

## Conclusion

In contrast to its catabolic effects on carbohydrate and lipid metabolism, the SNS, through adrenal medulla-secreted catecholamines, and norepinephrine released by adrenergic terminals exerts anabolic action on skeletal muscle protein metabolism. In addition to the intrinsic regulation of calpain by the  $\text{Ca}^{2+}$ -requirement for the enzyme activity, and by levels, activity and isoform types of calpastatin, catecholamines may contribute to maintain muscle  $\text{Ca}^{2+}$ -dependent proteolysis inhibited through a  $\beta_2$ -

adrenoceptor/cAMP-mediated phosphorylation of components of the calpain system, including CREB and calpastatin. In oxidative muscles, such as soleus, at least part of these effects can also be mediated by  $\beta_3$ -adrenoceptors. This antiproteolytic effect seems to be important for the preservation of muscle structure and function, mainly in oxidative postural muscles in both basal conditions and during stress situations. The anabolic actions of synthetic catecholamines and/or cAMP-phosphodiesterase inhibitors may also have therapeutic value in the treatment of muscle-wasting conditions, such as diabetes and sepsis, and may enhance muscle growth in farm animals for economic and nutritional purposes. This emphasizes the necessity of further studies to clarify the molecular mechanisms involved with the adrenergic control of protein metabolism in skeletal muscle.

## Acknowledgments

We are indebted to Neusa M. Zanon and Maria Antonieta R. Garófalo (Departamento de Fisiologia), Elza Aparecida Filippin and Victor Diaz Galbán (Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil) for technical assistance.

## References

- Barker D, Saito M. Autonomic innervation of receptors and muscle fibres in cat skeletal muscle. *Proc R Soc Lond B Biol Sci* 1981; 212: 317-332.
- Omori K, Kotera J. Overview of PDEs and their regulation. *Circ Res* 2007; 100: 309-327.
- Bloom TJ. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. *Can J Physiol Pharmacol* 2002; 80: 1132-1135.
- Landsberg L, Young JB. Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW (Editors), *Williams textbook of endocrinology*. 8th edn. Philadelphia: WB Saunders; 1992. p 621-705.
- Chaves VE, Frasson D, Martins-Santos ME, Navegantes LC, Galban VD, Garofalo MA, et al. Fatty acid synthesis and generation of glycerol-3-phosphate in brown adipose tissue from rats fed a cafeteria diet. *Can J Physiol Pharmacol* 2008; 86: 416-423.
- Bartness TJ, Song CK. Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. *J Lipid Res* 2007; 48: 1655-1672.
- Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. *Physiol Rev* 2008; 88: 729-767.
- Reeds PJ, Hay SM, Dorwood PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. *Br J Nutr* 1986; 56: 249-258.
- Lynch GS, Schertzer JD, Ryall JG. Anabolic agents for improving muscle regeneration and function after injury. *Clin Exp Pharmacol Physiol* 2008; 35: 852-858.
- Navegantes LC, Migliorini RH, do Carmo Kettelhut I. Adrenergic control of protein metabolism in skeletal muscle. *Curr Opin Clin Nutr Metab Care* 2002; 5: 281-286.
- Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. *Int J Biochem Cell Biol* 2005; 37: 1974-1984.
- Sandri M. Signaling in muscle atrophy and hypertrophy. *Physiology* 2008; 23: 160-170.
- Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Effect of guanethidine-induced adrenergic blockade on the different proteolytic systems in rat skeletal muscle. *Am J Physiol* 1999; 277: E883-E889.
- Picklo MJ. Methods of sympathetic degeneration and alteration. *J Auton Nerv Syst* 1997; 62: 111-125.
- Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle. *Am J Physiol Endocrinol Metab* 2000; 279: E663-E668.

16. Rosdahl H, Samuelsson AC, Ungerstedt U, Henriksson J. Influence of adrenergic agonists on the release of amino acids from rat skeletal muscle studied by microdialysis. *Acta Physiol Scand* 1998; 163: 349-360.
17. Kadowaki M, Kamata T, Noguchi T. Acute effect of epinephrine on muscle proteolysis in perfused rat hindquarters. *Am J Physiol* 1996; 270: E961-E967.
18. Shamoon H, Jacob R, Sherwin RS. Epinephrine-induced hypoaminoacidemia in normal and diabetic human subjects: effect of beta blockade. *Diabetes* 1980; 29: 875-881.
19. Baviera AM, Zanon NM, Navegantes LC, Migliorini RH, Kettelhut IC. Chemical sympathectomy further increases muscle protein degradation of acutely diabetic rats. *Muscle Nerve* 2008; 38: 1027-1035.
20. Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Catecholamines inhibit Ca<sup>2+</sup>-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. *Am J Physiol Endocrinol Metab* 2001; 281: E449-E454.
21. Sensky PL, Parr T, Bardsley RG, Buttery PJ. The relationship between plasma epinephrine concentration and the activity of the calpain enzyme system in porcine longissimus muscle. *J Anim Sci* 1996; 74: 380-387.
22. Viguerie N, Clement K, Barbe P, Courtine M, Benis A, Larrouy D, et al. *In vivo* epinephrine-mediated regulation of gene expression in human skeletal muscle. *J Clin Endocrinol Metab* 2004; 89: 2000-2014.
23. Hoover F, Mathiesen I, Skalhegg BS, Lomo T, Tasken K. Differential expression and regulation of the PKA signalling pathway in fast and slow skeletal muscle. *Anat Embryol* 2001; 203: 193-201.
24. Jensen J, Brennesvik EO, Bergersen H, Oseland H, Jebens E, Brors O. Quantitative determination of cell surface beta-adrenoceptors in different rat skeletal muscles. *Pflugers Arch* 2002; 444: 213-219.
25. Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. *Am J Physiol* 1992; 263: E50-E56.
26. Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, et al. The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. *Int J Obes Relat Metab Disord* 1999; 23: 1057-1065.
27. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. *Science* 1989; 245: 1118-1121.
28. Reeds PJ, Hay SM, Dorwood PM, Palmer RM. The effect of  $\beta$ -agonists and antagonists on muscle growth and body composition of young rats (*Rattus* sp). *Comp Biochem Physiol* 1998; 89C: 337-341.
29. Board M, Doyle P, Cawthorne MA. BRL37344, but not CGP12177, stimulates fuel oxidation by soleus muscle *in vitro*. *Eur J Pharmacol* 2000; 406: 33-40.
30. Navegantes LC, Resano NM, Baviera AM, Migliorini RH, Kettelhut IC. CL 316,243, a selective beta3-adrenergic agonist, inhibits protein breakdown in rat skeletal muscle. *Pflugers Arch* 2006; 451: 617-624.
31. Goll DE, Neti G, Mares SW, Thompson VF. Myofibrillar protein turnover: the proteasome and the calpains. *J Anim Sci* 2008; 86: E19-E35.
32. Goll DE, Thompson VF, Taylor RG, Ouali A. The calpain system and skeletal muscle growth. *Can J Anim Sci* 1998; 78: 503-512.
33. Kumamoto T, Kleese WC, Cong JY, Goll DE, Pierce PR, Allen RE. Localization of the Ca<sup>2+</sup>-dependent proteinases and their inhibitor in normal, fasted, and denervated rat skeletal muscle. *Anat Rec* 1992; 232: 60-77.
34. Goll DE, Thompson VF, Taylor RG, Ouali A, Chow R-GR. The calpain system in muscle tissue. In: Wang K, Yuens P (Editors), *Calpain: pharmacology and toxicology of calcium-dependent protease*. Philadelphia: Taylor & Francis; 1999. p 127-160.
35. Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. *Biol Chem* 2004; 385: 465-472.
36. Otani K, Han DH, Ford EL, Garcia-Roves PM, Ye H, Horikawa Y, et al. Calpain system regulates muscle mass and glucose transporter GLUT4 turnover. *J Biol Chem* 2004; 279: 20915-20920.
37. Tidball JG, Spencer MJ. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. *J Physiol* 2002; 545: 819-828.
38. Zoccal DB, Bonagamba LG, Oliveira FR, Antunes-Rodrigues J, Machado BH. Increased sympathetic activity in rats submitted to chronic intermittent hypoxia. *Exp Physiol* 2007; 92: 79-85.
39. Zoccal DB, Simms AE, Bonagamba LG, Braga VA, Pickering AE, Paton JF, et al. Increased sympathetic outflow in juvenile rats submitted to chronic intermittent hypoxia correlates with enhanced expiratory activity. *J Physiol* 2008; 586: 3253-3265.
40. Parr T, Sensky PL, Arnold MK, Bardsley RG, Buttery PJ. Effects of epinephrine infusion on expression of calpastatin in porcine cardiac and skeletal muscle. *Arch Biochem Biophys* 2000; 374: 299-305.
41. Parr T, Sensky PL, Bardsley RG, Buttery PJ. Calpastatin expression in porcine cardiac and skeletal muscle and partial gene structure. *Arch Biochem Biophys* 2001; 395: 1-13.
42. Salem M, Levesque H, Moon TW, Rexroad CE, Yao J. Anabolic effects of feeding beta2-adrenergic agonists on rainbow trout muscle proteases and proteins. *Comp Biochem Physiol A Mol Integr Physiol* 2006; 144: 145-154.
43. Vissing K, Overgaard K, Nedergaard A, Fredsted A, Schjerling P. Effects of concentric and repeated eccentric exercise on muscle damage and calpain-calpastatin gene expression in human skeletal muscle. *Eur J Appl Physiol* 2008; 103: 323-332.
44. Cong M, Thompson VF, Goll DE, Antin PB. The bovine calpastatin gene promoter and a new N-terminal region of the protein are targets for cAMP-dependent protein kinase activity. *J Biol Chem* 1998; 273: 660-666.
45. Salamino F, De Tullio R, Michetti M, Mengotti P, Melloni E, Pontremoli S. Modulation of calpastatin specificity in rat tissues by reversible phosphorylation and dephosphorylation. *Biochem Biophys Res Commun* 1994; 199: 1326-1332.
46. Pontremoli S, Viotti PL, Michetti M, Salamino F, Sparatore B, Melloni E. Modulation of inhibitory efficiency of rat skeletal muscle calpastatin by phosphorylation. *Biochem Biophys Res Commun* 1992; 187: 751-759.
47. Sensky PL, Jewell KK, Ryan KJ, Parr T, Bardsley RG, Buttery PJ. Effect of anabolic agents on calpastatin promot-

- ers in porcine skeletal muscle and their responsiveness to cyclic adenosine monophosphate- and calcium-related stimuli. *J Anim Sci* 2006; 84: 2973-2982.
48. Navegantes LC, Machado CR, Resano NM, Migliorini RH, Kettelhut IC. Beta2-agonists and cAMP inhibit protein degradation in isolated chick (*Gallus domesticus*) skeletal muscle. *Br Poult Sci* 2003; 44: 149-154.
  49. Hinkle RT, Dolan E, Cody DB, Bauer MB, Isfort RJ. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. *Muscle Nerve* 2005; 32: 775-781.
  50. Jurasinski CV, Kilpatrick L, Vary TC. Amrinone prevents muscle protein wasting during chronic sepsis. *Am J Physiol* 1995; 268: E491-E500.
  51. Combaret L, Rallièrre C, Taillandier D, Tanaka K, Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. *Mol Biol Rep* 1999; 26: 95-101.
  52. Breuille D, Farge MC, Rose F, Arnal M, Attaix D, Oblet C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. *Am J Physiol* 1993; 265: E660-E666.
  53. Lira EC, Graça FA, Goncalves DA, Zanon NM, Baviera AM, Strindberg L, et al. Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats. *Shock* 2007; 27: 687-694.
  54. Baviera AM, Zanon NM, Carvalho Navegantes LC, Migliorini RH, do Carmo Kettelhut I. Pentoxifylline inhibits Ca<sup>2+</sup>-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. *Am J Physiol Endocrinol Metab* 2007; 292: E702-E708.
  55. Pepato MT, Migliorini RH, Goldberg AL, Kettelhut IC. Role of different proteolytic pathways in degradation of muscle protein from streptozotocin-diabetic rats. *Am J Physiol* 1996; 271: E340-E347.
  56. Brennesvik EO, Ktori C, Ruzzin J, Jebens E, Shepherd PR, Jensen J. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. *Cell Signal* 2005; 17: 1551-1559.
  57. Shiraha H, Glading A, Chou J, Jia Z, Wells A. Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. *Mol Cell Biol* 2002; 22: 2716-2727.
  58. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. *J Appl Physiol* 2007; 102: 740-747.
  59. Yimlamai T, Dodd SL, Borst SE, Park S. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. *J Appl Physiol* 2005; 99: 71-80.